After becoming the first CMO in the world to implement the 2000L scale Xcellerex™ single-use bioreactor at our Durham, NC, USA site, KBI Biopharma immediately began delivering GMP Drug Substance supplying FIH (First in Human) and clinical resupply programs.
In 2014, our proven track record for drug substance delivery facilitated manufacturing suite space expansion, adding another Seed Expansion, 500L→2000L bioreactor train, and purification suite.
In 2022, KBI expanded our clinical mammalian cGMP manufacturing capabilities within our site in Geneva, Switzerland, mirroring the Seed Expansion, 500L→2000L bioreactor train, and purification suite.
Learn more about KBI’s deployment of single-use technologies
Our multi-product manufacturing facilities provide robust product segregation, pre-and post-viral downstream processing areas, and cross-contamination prevention.
The segregated HVAC design and personnel, material, and equipment flow together with the deployment of end-to-end single-use technology allow for maximum flexibility and rapid turn-around, all the while protecting your timelines and investment.
Learn more about our cGMP biologics manufacturing services
The mainstay of this success is our greatest asset - our team members. We are a diverse collection of experienced industry professionals, who understand the impact these new proteins, antibodies, and vaccines have on human health and put our hearts and experiences to work delivering outstanding quality products.
We expect you will feel right at home as you come to know KBI Manufacturing and our commitment to your company and your molecules.
4x (500L→2000L)
bioreactor train & purification suite
Multiple Trains
single-use (disposable) technology
24x7
manufacturing operations
